Is immunotherapy in the future of therapeutic management of sarcomas?

被引：24

作者：

Clemente, Ottavia ^{[1
]}

Ottaiano, Alessandro ^{[2
]}

Di Lorenzo, Giuseppe ^{[1
]}

Bracigliano, Alessandra ^{[3
]}

Lamia, Sabrina ^{[1
]}

Cannella, Lucia ^{[1
]}

Pizzolorusso, Antonio ^{[1
]}

Di Marzo, Massimiliano ^{[4
]}

Santorsola, Mariachiara ^{[2
]}

De Chiara, Annarosaria ^{[5
]}

Fazioli, Flavio ^{[6
]}

Tafuto, Salvatore ^{[1
]}

机构：

[1] IRCCS Fdn G Pascale, Sarcomas & Rare Tumors Unit, Ist Nazl Tumori, I-80131 Naples, Italy

[2] IRCCS Fdn G Pascale, Div Innovat Therapies, Ist Nazl Tumori, I-80131 Naples, Italy

[3] IRCCS Fdn G Pascale, Nucl Med Unit, Ist Nazl Tumori, I-80131 Naples, Italy

[4] IRCCS Fdn G Pascale, Dept Abdominal Oncol, Ist Nazl Tumori, I-80131 Naples, Italy

[5] IRCCS Fdn G Pascale, Ist Nazl Tumori, Histopathol Lymphomas & Sarcomas SSD, I-80131 Naples, Italy

[6] IRCCS Fdn G Pascale, Orthoped Oncol Unit, Ist Nazl Tumori, I-80131 Naples, Italy

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2021年 / 19卷 / 01期

关键词：

Soft tissue sarcoma; Osteosarcoma; Immunotherapy; Anti-cancer vaccine; CAR-T therapy; SOFT-TISSUE SARCOMA; TUMOR-INFILTRATING LYMPHOCYTES; T-CELL-RECEPTOR; TARGETED ONCOLYTIC POXVIRUS; HUMORAL IMMUNE-RESPONSE; CANCER-TESTIS ANTIGEN; PHASE-I TRIAL; SYNOVIAL SARCOMA; BONE SARCOMA; OPEN-LABEL;

D O I：

10.1186/s12967-021-02829-y

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Sarcomas are rare, ubiquitous and heterogeneous tumors usually treated with surgery, chemotherapy, target therapy, and radiotherapy. However, 25-50% of patients experience local relapses and/or distant metastases after chemotherapy with an overall survival about 12-18 months. Recently, immuno-therapy has revolutionized the cancer treatments with initial indications for non-small cell lung cancer (NSCLC) and melanoma (immune-checkpoint inhibitors).Here, we provide a narrative review on the topic as well as a critical description of the currently available trials on immunotherapy treatments in patients with sarcoma. Given the promising results obtained with anti-PD-1 monoclonal antibodies (pembrolizumab and nivolumab) and CAR-T cells, we strongly believe that these new immunotherapeutic approaches, along with an innovative characterization of tumor genetics, will provide an exciting opportunity to ameliorate the therapeutic management of sarcomas.

引用

页数：24

共 155 条

[1] Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy [J].

Achard, Carole ;

Surendran, Abera ;

Wedge, Marie-Eve ;

Ungerechts, Guy ;

Bell, John ;

Ilkow, Carolina S. .

EBIOMEDICINE, 2018, 31 :17-24

[2] Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].

Ahmed, Nabil ;

Brawley, Vita S. ;

Hegde, Meenakshi ;

Robertson, Catherine ;

Ghazi, Alexia ;

Gerken, Claudia ;

Liu, Enli ;

Dakhova, Olga ;

Ashoori, Aidin ;

Corder, Amanda ;

Gray, Tara ;

Wu, Meng-Fen ;

Liu, Hao ;

Hicks, John ;

Rainusso, Nino ;

Dotti, Gianpietro ;

Mei, Zhuyong ;

Grilley, Bambi ;

Gee, Adrian ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Wels, Winfried S. ;

Wang, Lisa L. ;

Anderson, Peter ;

Gottschalk, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+

[3] Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma [J].

Andtbacka, Robert H. I. ;

Amatruda, Thomas ;

Nemunaitis, John ;

Zager, Jonathan S. ;

Walker, John ;

Chesney, Jason A. ;

Liu, Kate ;

Hsu, Cheng-Pang ;

Pickett, Cheryl A. ;

Mehnert, Janice M. .

EBIOMEDICINE, 2019, 47 :89-97

[4] Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial [J].

Atkins, Michael B. ;

Plimack, Elizabeth R. ;

Puzanov, Igor ;

Fishman, Mayer N. ;

McDermott, David F. ;

Cho, Daniel C. ;

Vaishampayan, Ulka ;

George, Saby ;

Olencki, Thomas E. ;

Tarazi, Jamal C. ;

Rosbrook, Brad ;

Fernandez, Kathrine C. ;

Lechuga, Mariajose ;

Choueiri, Toni K. .

LANCET ONCOLOGY, 2018, 19 (03) :405-415

[5]

Ayyoub Maha, 2004, Cancer Immun, V4, P7

[6] Adjuvant chemotherapy in soft tissue sarcomas. Conflicts, consensus, and controversies [J].

Bajpai, Jyoti ;

Susan, Deepa .

SOUTH ASIAN JOURNAL OF CANCER, 2016, 5 (01) :15-+

[7]

BAKER JC, 1987, J BIOL CHEM, V262, P14855

[8]

BALCH CM, 1990, ARCH SURG-CHICAGO, V125, P200

[9] Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept [J].

Berghmans, Thierry ;

Durieux, Valerie ;

Hendriks, Lizza E. L. ;

Dingemans, Anne-Marie .

FRONTIERS IN MEDICINE, 2020, 7

[10] Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression [J].

Berghuis, Dagmar ;

Santos, Susy J. ;

Baelde, Hans J. ;

Taminiau, Antonie H. M. ;

Egeler, R. Maarten ;

Schilham, Marco W. ;

Hogendoorn, Pancras C. W. ;

Lankester, Arjan C. .

JOURNAL OF PATHOLOGY, 2011, 223 (03) :347-357

← 1 2 3 4 5 6 7 8 9 10 →